Skip to main content

Table 1 Patients characteristics treated with first line induction TPF chemotherapy

From: CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer

 

Overall

 

n = 78

Age (years)

 

 Median

56

 Range

40–72

>60 years (%)

28.2

Sex

 

 Male

n = 69 (88.5 %)

 Female

n = 9 (11.5 %)

Treatment after TPF (%)

 

 RT

n = 69 (88.5 %)

 OP

n = 4 (5.1 %)

 no further treatment due to toxicity

n = 5 (6.4 %)

Nodal stage cN2c or cN3

 

 Yes

n = 24 (30.8 %)

 No

n = 54 (69.2 %)

cT4 stage (%)

 

 Yes

n = 53 (67.9 %)

 No

n = 25 (32.1)

Stage of disease

 

 AJCC Stage 4

n = 73 (93.4 %)

 AJCC Stage 3

n = 5 (6.4 %)

Localisation of primary tumor (%)

 

 Oral cavity

n = 12 (15.4 %)

 Pharynx

n = 63 (80.7 %)

 Paranasal sinus

n = 2 (2.6 %)

 Not available

n = 1 (1.3 %)

  1. TPF docetaxel, 5-flurouracil, cisplatin
  2. CUP carcinoma of unknown primary
  3. RT radiotherapy
  4. n number
  5. AJCC American Joint Committee on Cancer